Peptides DB
Research-centric peptide and protocol reference hub
Study 5 of 18Gonadorelin (GnRH) literatureeuropepmc · Case report2026

Central precocious puberty in partial androgen insensitivity syndrome: a 9-year follow-up.

This case underscores the diagnostic challenges and treatment complexities associated with partial androgen insensitivity syndrome and central precocious puberty.

Read at europepmcAdd to compare

Where it sits

this study against the rest of the gonadorelin (gnrh) corpus
0
Preclinical
17
Observational · this one
0
Open-label
1
Randomised
0
Reviews

Summary and findings

This case study reports on a 2-year-1-month-old boy diagnosed with partial androgen insensitivity syndrome (AIS) who developed central precocious puberty. The patient underwent multiple treatments, including oral letrozole and tamoxifen, following the diagnosis. The study emphasizes the need for long-term multidisciplinary care due to the complexity of symptoms.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as europepmc supplied them

Androgen insensitivity syndrome (AIS) is a group of complex clinical symptoms caused by X-linked genetic defects. It results from inactivating mutations in the <i>androgen receptor (AR) g</i>ene, leading to hormone resistance in individuals with an XY karyotype despite normal androgen synthesis. We present a case of a 2-year-1-month-old boy who initially showed signs of incomplete masculinization of the external genitalia and underwent transverse preputial island flap urethroplasty during childhood. At the age of 7, he presented with gynecomastia, accompanied by accelerated growth and advanced bone age, with significantly elevated serum sex hormone levels. During this period, epididymitis recurred repeatedly. Genetic testing indicated a pathogenic mutation in the androgen receptor gene. The diagnosis of partial AIS with central precocious puberty was established, and treatment was initiated sequentially with oral letrozole and tamoxifen. The patient underwent multiple surgical procedures and experienced distress related to breast development. A review of the literature indicates that most patients with AIS present with delayed puberty; to date, only 2 cases of AIS combined with central precocious puberty have been reported. This case highlights diagnostic challenges, treatment considerations, and the importance of long-term multidisciplinary care, and further delineates the clinical phenotype.

Background

This paper addresses the long-term management of central precocious puberty in individuals diagnosed with partial androgen insensitivity syndrome. Previous literature has indicated that precocious puberty can lead to various psychosocial and physical complications, making effective management crucial. Understanding the outcomes over a significant follow-up period is essential for informing clinical practices.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.

Elsewhere in the Gonadorelin (GnRH) corpus

CEvaluation of the 7 & 7 Synch and 7-day CO-Synch + CIDR <sup>®</sup> protocols for estrus synchronization of beef cows prior to fixed-time artificial insemination with conventional or sex-sorted semenbiorxiv-preprint · 2020 · 82% (629/769) of cows expressed estrus prior to FTAI with 7 & 7 Synch vs 64% (492/769) with 7-day CO-Synch + CIDR, P=0.01.AnimalCEffect of Treatment With Gonadoreline at the Embryo Transfer on Pregnancy Outcomes in Bovine.biorxiv-preprint · 2021 · Conception rate at 30 days: 45.8% in treated group vs control, p=0.03.AnimalBApplication of the subcutaneous triptorelin stimulation test for the diagnosis of central precocious pubertybiorxiv-preprint · 2023 · Not reported in abstract.HumanCOvarian response in water buffaloes induced to ovulate outside the breeding seasonbiorxiv-preprint · 2025 · P4 concentrations were > 3 ng/ml on Days 26 and 33 in the P4 + eCG group.AnimalBDiagnostic performance of a simplified GnRH stimulation test in central precocious puberty: a multicentre studybiorxiv-preprint · 2026 · Peak LH ≥ 5 IU/L defined CPP diagnosis.HumanBIncidence study of precocious puberty in the population of the state of Goiás: did the COVID-19 pandemic modify the epidemiology?PubMed · 2026 · 154% increase in treatment requests during the pandemic, p<0.001.Human